SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are actively debating the long-term viability of the SpaceX IPO, with bulls highlighting the company's ambitious infrastructure goals and potential for future index inclusion, while bears warn of extreme overvaluation and persistent cash burn. Community discourse remains polarized between those viewing this as a generational buy and others cautioning against significant downside risk as the initial hype meets real-world fundamentals.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is experiencing significant volatility and downward pressure as investors rotate out of the fund to pursue direct exposure to the upcoming SpaceX IPO, which has triggered widespread selling despite the fund's heavy concentration in high-growth private tech assets. The community remains deeply divided, with some investors aggressively adding to positions on the belief that current market prices trade at a steep discount to the fund's true net asset value, while others are frustrated by management's dilution through share offerings and a lack of communication regarding the fund's underlying valuation.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

Investors are expressing frustration over the ETF's lack of upward momentum despite its concentrated holding in SpaceX, with many in the community debating the impact of the fund's SPV-based valuation structure versus direct equity exposure. Discussions focus on whether the market is discounting the fund's private asset holdings ahead of a broader public launch or if the current price action reflects concerns regarding transparency and the fund's long-term growth potential.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing heavy volatility and downward pressure as capital rotates into the high-profile SpaceX IPO, creating a liquidity vacuum across the space sector. Despite the selling, community members remain focused on the upcoming launch of new satellites as a critical catalyst to validate long-term growth and spark a recovery.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors weigh potential antitrust hurdles, including reports of state-level lawsuits, against the company's efforts to finalize its major acquisition of Warner Bros. Discovery. While some community members remain focused on regulatory timelines and the strategic integration of content, others are actively debating the potential impact on share price and the long-term viability of the combined entity.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are experiencing significant volatility and trading volume following reports that the streaming platform is engaged in early-stage buyout discussions with a major media company. While investors are debating the credibility of these rumors and the potential valuation, the community is actively discussing the company's long-term potential in the ad-supported streaming market and the implications of a possible consolidation deal.

ROAM Token

The ROAM community is generating significant buzz around the intersection of its decentralized connectivity network, eSIM travel utility, and a new AI-driven creative challenge. Supporters are highlighting the project's real-world infrastructure growth and its transition into an AI-ready ecosystem, while debate continues regarding its marketing strategy and long-term token utility.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the community highlights the stock's role in the critical semiconductor supply chain, specifically through its expanding advanced packaging and testing infrastructure in Arizona. Investors are actively discussing the "Z-Axis Trade," a theme focused on packaging companies that are essential for scaling AI compute, with many noting a broad-based rotation into these manufacturers as they hit new 52-week highs.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing attention as investors rotate toward quality-tilted, dividend-growth strategies to balance portfolio volatility. The community remains focused on long-term accumulation, with ongoing discussions emphasizing the fund's role as a core defensive anchor that provides income stability through market cycles.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors digest positive clinical data for its subcutaneous Briumvi treatment and speculate on potential buyout interest, despite some frustration over recent share price volatility. The community is actively debating the stock's long-term value, the possibility of a premium acquisition, and the competitive advantage Briumvi holds against established market alternatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study

Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Canaccord Genuity Group started coverage on Kymera Therapeutics in a report on Wednesday. They issued a 'buy' rating and a $106.00 target price for the company...

UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR

UBS Group AG lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and...

Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report released on Monday, May 4th. HC Wainwright analyst A. Fein now expects that the company will post earnings pe...

Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR

Jennison Associates LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 496,665 shares of the company's sto...

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration 

Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.

Kymera Therapeutics (NASDAQ:KYMR) Posts Earnings Results, Beats Expectations By $0.18 EPS

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus...

Kymera Therapeutics Q1 Earnings Call Highlights

Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update during its first-quarter 2026 results call, with executives emphasizing...

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Current Price	$86.21
Prev Close	$82.96
Open	$82.53
Dividend Yield	0.00%
50-Day Moving Average	$82.83
Beta	1.58
Avg. Volume	486,409.59
PE Ratio	-23.23

52-Week High	$103.00
52-Week Low	$36.65
Market Capitalization	$6.82B
EPS (Annual)	-$3.69
Price to Book	4.43
Revenue Per Employee	$164,752.10

KYMRKymera Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KYMR News